AllMade Raises Pre-Series A for Quantum Dot Diagnostics

South Korean innovator AllMade has successfully initiated its pre-Series A funding, drawing capital from Kookmin University Technology Holdings and Minetta Brook Ventures. This crucial early-stage investment will fuel the commercialization of the company's advanced point-of-care diagnostic platforms, which leverage cutting-edge quantum dot technology.

The company is focused on refining its in-vitro diagnostic system, a sophisticated platform that utilizes quantum-dot luminescence signals. Since its inception in 2025, AllMade has been dedicated to developing high-sensitivity diagnostic tools and precision sensing systems. These systems integrate bio-materials with quantum dots, ultra-fine semiconductor particles known for emitting specific colors based on their size, enabling highly accurate and rapid detection of various biomarkers.

This funding injection is earmarked to accelerate AllMade's go-to-market strategy. The company aims to expedite the global validation of its products and drive early revenue streams. Demonstrating market traction, AllMade recently showcased its rapid diagnostic kits for inflammatory bowel disease (Calprotectin) and colorectal cancer (FOB) at international medical expos in Vietnam. The positive reception from potential buyers at these events underscores the demand for AllMade's non-invasive testing solutions.

Further solidifying its international ambitions, AllMade plans to exhibit at the upcoming Medical Fair Asia in Singapore. This strategic participation is intended to bolster its export capabilities and establish a stronger foothold in overseas markets. The company previously secured seed funding in April 2025 from the Big Bang High Tech Bio Investment Fund, managed by Big Bang Ventures, indicating a consistent trajectory of investor confidence.

Minetta Brook Ventures' co-CEOs, Ji-cheol Kim and Tae-hoon Koo, expressed strong conviction in AllMade's potential. They highlighted the company's deep-tech approach, combining quantum-dot diagnostics with a significant market opportunity in non-invasive testing. Their continued support, including potential recommendations for R&D funding through programs like TIPS, signals a long-term commitment to AllMade's growth within the competitive domestic and international in-vitro diagnostics sectors.

Taek-kyu Oh, CEO of AllMade, emphasized the company's strategic direction. He noted the proven demand for point-of-care diagnostics and the encouraging feedback from international buyers. With the pre-Series A round nearing completion, AllMade is set to finalize its quantum-dot platform commercialization and intensify its global market penetration efforts, positioning itself as a key player in the rapidly evolving diagnostics industry.